All AbMole products are for research use only, cannot be used for human consumption.
Tizaterkib (AZD0364) is a potent and selective oral inhibitor of ERK1/2 which are ubiquitously expressed MAPK kinases that participate in the RAS- RAF- MEK- ERK signalling cascade in the regulation of cell cycle progression, cell proliferation, survival, metab. and transcription. AZD-0364 can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as a monotherapy.
In vivo, in the A549 xenograft model, Selumetinib is dosed twice daily (BiD) 8 hours apart and AZD-0364 ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and AZD-0364 ethanesulfonic acid reduce tumor growth relative to vehicle only control.
| Cell Experiment | |
|---|---|
| Cell lines | KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) A549, H2122, H2009, and Calu6 cell lines |
| Preparation method | KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) A549, H2122, H2009, and Calu6 cell lines are seeded in 384-well black, clear bottomed plates, cultured for 18-24 hours and treated with increasing concentrations of AZD-0364 (7.143 nM, 61 nM, 357 nM, 2.143 μM and 10 μM) and Selumetinib (0-10 μM) in a 6×6 dosing matrix. Cells are seeded at a concentration such that cells in untreated wells are approximately 80% confluent at the end of the assay. After 3 days of treatment, live cell number is determined using a Sytox Green endpoint. |
| Concentrations | 7.143 nM, 61 nM, 357 nM, 2.143 μM and 10 μM |
| Incubation time | 3 days |
| Animal Experiment | |
|---|---|
| Animal models | Female nude mice implanted subcutaneously (s.c.) on the left flank, with 5×106 A549 cells |
| Formulation | |
| Dosages | 25 mg/kg QD (four hours after first Selumetinib dose) |
| Administration | peroral route |
| Molecular Weight | 494.50 |
| Formula | C24H24F2N8O2 |
| CAS Number | 2097416-76-5 |
| Solubility (25°C) | DMSO: ≥ 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related ERK Products |
|---|
| SCH772984
SCH772984 is a novel and selective inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively. |
| FR 180204
FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively. |
| GDC-0994
Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with IC50 of 6.1 nM and 3.1 nM against ERK1 and ERK2, respectively. |
| Astragaloside IV
Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. |
| Corynoxeine
Corynoxeine, isolated from the hook of Uncaria Rhynchophylla, is a potent ERK1/ERK 2 inhibitor in the proliferation of PDGF-BB induced vascular smooth muscle cells (VSMCs). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
